The Latest Breaking News from Eli Lilly

Eli Lilly shares are down 17.7% from its highs. The company posted 128% YoY revenue jump in its Mounjaro GLP-1/GIP treatment with no signs of slowing down.

The pharma giant’s stock has been under pressure since the Greenland issue has been in the spotlight.

All-Pro safety Brian Dawkins comments on how NFL defenses have adjusting to the league's changing rules w/ @EdEastonJr

Eli Lilly, plus two other massive companies, just announced double-digit percentage increases in their quarterly dividend payments.

Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.

The healthcare industry is set for growth due to the growing demand for quality treatments and ongoing progress in medical technology. Hence, investors might consider investing in healthcare stocks, Eli Lilly (LLY), Thermo Fisher Scientific (TMO), and Abbott Laboratories (ABT) for a healthy portfolio in 2025. Read more….

Construction on the facility in Kenosha County, Wis., is expected to begin next year.

Eli Lilly invests billion to boost manufacturing capabilities, expanding in Wisconsin and Indianapolis to meet growing market demand.

Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products